[go: up one dir, main page]

WO2009147178A3 - Substituted pyridin-2-ylmethylsulphinyl-1h-benzimidaz0les for use in the treatment of brain edema - Google Patents

Substituted pyridin-2-ylmethylsulphinyl-1h-benzimidaz0les for use in the treatment of brain edema Download PDF

Info

Publication number
WO2009147178A3
WO2009147178A3 PCT/EP2009/056824 EP2009056824W WO2009147178A3 WO 2009147178 A3 WO2009147178 A3 WO 2009147178A3 EP 2009056824 W EP2009056824 W EP 2009056824W WO 2009147178 A3 WO2009147178 A3 WO 2009147178A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
ylmethylsulphinyl
brain edema
substituted pyridin
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/056824
Other languages
French (fr)
Other versions
WO2009147178A2 (en
Inventor
Hartmut Heinze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of WO2009147178A2 publication Critical patent/WO2009147178A2/en
Publication of WO2009147178A3 publication Critical patent/WO2009147178A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention is directed to a new use of substituted pyridyl-2-methylsulfinylbenzinnidazoles for a treatment and/or prophylaxis of brain edema.
PCT/EP2009/056824 2008-06-04 2009-06-03 Novel medical use of substituted pyridin-2-ylmethylsulphinyl-1h-benzimidazoles Ceased WO2009147178A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157528 2008-06-04
EP08157528.4 2008-06-04

Publications (2)

Publication Number Publication Date
WO2009147178A2 WO2009147178A2 (en) 2009-12-10
WO2009147178A3 true WO2009147178A3 (en) 2010-03-18

Family

ID=39870104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056824 Ceased WO2009147178A2 (en) 2008-06-04 2009-06-03 Novel medical use of substituted pyridin-2-ylmethylsulphinyl-1h-benzimidazoles

Country Status (1)

Country Link
WO (1) WO2009147178A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2007064274A1 (en) * 2005-11-30 2007-06-07 Astrazeneca Ab Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2007064274A1 (en) * 2005-11-30 2007-06-07 Astrazeneca Ab Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JAVAHERI S ET AL: "Different effects of omeprazole and Sch 28080 on canine cerebrospinal fluid production", BRAIN RESEARCH 19970418 NL, vol. 754, no. 1-2, 18 April 1997 (1997-04-18), pages 321 - 324, XP007906112, ISSN: 0006-8993 *
JOCHEM V ET AL: "Fulminant hepatic failure related to omeprazole.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY APR 1992, vol. 87, no. 4, April 1992 (1992-04-01), pages 523 - 525, XP007906130, ISSN: 0002-9270 *
LINDVALL-AXELSSON M ET AL: "Inhibition of cerebrospinal fluid formation by omeprazole", EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 115, no. 3, 1 March 1992 (1992-03-01), pages 394 - 399, XP022980519, ISSN: 0014-4886, [retrieved on 19920301] *
RABINSTEIN ALEJANDRO A: "Treatment of cerebral edema", NEUROLOGIST, WLLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 12, no. 2, 1 May 2006 (2006-05-01), pages 59 - 73, XP009107834, ISSN: 1074-7931 *
RASLAN, BHARDWAJ: "Medical management of cerebral edema", NEUROSURG FOCUS, vol. 22, 2007, pages 1 - 12, XP007906107 *

Also Published As

Publication number Publication date
WO2009147178A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2012045089A3 (en) Methods for the treatment of allergic diseases
MX2010007490A (en) Preparation of sulfamide derivatives.
IN2012DN00624A (en)
MX2009013353A (en) Telomerase activating compounds and methods of use thereof.
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
AU2007208169A8 (en) Use of gallium to treat biofilm-associated infectons
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
IL207220A0 (en) Methods for the treatment and prevention of age-related retinal dysfunction
WO2011163452A8 (en) Treating surface of the eye disorders
WO2011071995A9 (en) Compounds and methods of treating ocular disorders
IL210997A0 (en) Compositions for the treatment of mrsa and uses thereof
WO2013098416A3 (en) Pain relief compounds
IN2014CN04014A (en)
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
IL210953A0 (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
IL207965A (en) Compounds for use in the treatment or prophylaxis of pain
EP2207555A4 (en) Novel compounds for the treatment or alleviation of edema, and methods for their use
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
MX2013002121A (en) Substituted quinoline-3-carboxamides as kcnq2/3 modulators.
PT3330383T (en) Grn163l for use as telomerase inhibitor in the treatment of cancer
WO2009123486A8 (en) Use of compounds in the treatment of tau-induced cytotoxicities
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
IL215235A (en) Pyrazole compound, medicament comprising the compound and use of the compound for the production of an agent for the prophylaxis or treatment of peptic ulcer
MX2011013324A (en) Use of substituted oxindole derivatives for the treatment and prophylaxis of pain.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757559

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09757559

Country of ref document: EP

Kind code of ref document: A2